| Course | DNP 820 Health Policy and Advocacy |
|---|---|
| Module | Module 3 |
| Paper type | Federal law analysis |
| Length | About 1,014 words, 6 pages |
| Format | APA 7 student paper |
| School | Aspen University |
| Program | DNP |
| Updated | September 2026 |
Free sample paper for DNP 820 Module 3
No More X: Federal Law, Buprenorphine and the Advanced Practice Nurse's Role in Treating Opioid Use Disorder
Student Name
Doctor of Nursing Practice Program, Aspen University
DNP 820: Health Policy and Advocacy
Instructor Name
Month Day, Year
No More X: Federal Law, Buprenorphine and the Advanced Practice Nurse's Role in Treating Opioid Use Disorder
Buprenorphine is one of the most effective treatments for opioid use disorder, lowering illicit opioid use and cutting the chance of dying from an overdose. For nearly two decades, however, federal law required clinicians to obtain a special waiver, known as the X-waiver because of the letter added to their registration number, before prescribing it for addiction, and for part of that time nurse practitioners could not obtain one at all. This paper analyzes the sequence of federal laws that first opened buprenorphine prescribing to advanced practice registered nurses and then removed the waiver requirement, examines the evidence on their effects, considers how state law limits the federal change, and identifies the implications for advanced practice nurses.
The stakes are high. In a study of 40,885 commercially insured and Medicare Advantage adults with opioid use disorder, only treatment with buprenorphine or methadone was associated with a lower risk of overdose, with an adjusted hazard ratio of 0.24 at three months and 0.41 at twelve months, yet just 12.5% of patients received one of these medications (Wakeman et al., 2020). Other pathways, including detoxification and nonintensive behavioral health care, were not associated with fewer overdoses. Any legal barrier that reduces the number of clinicians willing to prescribe these medications therefore has consequences measured in lives.
The Legislative Sequence
The Drug Addiction Treatment Act of 2000 allowed physicians to prescribe buprenorphine for opioid use disorder in office settings if they obtained a waiver, completed training and accepted patient limits. Nurse practitioners and physician assistants were excluded. The Comprehensive Addiction and Recovery Act of 2016 temporarily allowed nurse practitioners and physician assistants to obtain waivers after completing 24 hours of training, three times the training required of physicians. The SUPPORT for Patients and Communities Act of 2018 made that authority permanent and extended eligibility to other advanced practice registered nurses, including clinical nurse specialists, certified nurse-midwives and nurse anesthetists. Finally, the Consolidated Appropriations Act, 2023, enacted at the end of December 2022, eliminated the waiver requirement entirely, so that any practitioner with a standard federal controlled substances registration that includes Schedule III may prescribe buprenorphine for opioid use disorder, subject to state law, and it added a one-time training requirement for new or renewed registrations for prescribers of controlled substances.
Evidence on the Effects
Evidence on the earlier expansion shows that nurse practitioners and physician assistants responded quickly, especially where physicians were scarce. Using federal data, one analysis found that the number of waivered clinicians per 100,000 people in rural areas increased by 111% from 2016 to 2019, that nurse practitioners and physician assistants accounted for more than half of that increase, and that they were the first waivered clinicians in many rural counties that had previously had none. In rural areas, broad scope-of-practice laws were associated with about twice as many waivered nurse practitioners per 100,000 people as restricted scopes (Barnett et al., 2019).
Another study linked waiver uptake to state practice restrictions, finding that nurse practitioners in states that required physician supervision or collaboration were less likely to obtain waivers than those in states with full practice authority (Spetz et al., 2019). These findings suggest that the federal law's effect depended heavily on state law, a pattern likely to continue after the waiver's removal.
State Law Still Matters
Removing the federal waiver did not remove state requirements. States determine whether nurse practitioners may prescribe controlled substances, whether they need a collaborative agreement or supervision, and whether additional state rules apply to buprenorphine. In states with restricted practice, a nurse practitioner may still need a physician collaborator willing to support addiction treatment, and some collaborating physicians decline. Some states have their own training or registration requirements for office-based opioid treatment. The federal change therefore widens access most in states with full practice authority and least where state law adds barriers, repeating the pattern seen with the waiver.
For an advanced practice nurse, this means reading the federal change together with the state nurse practice act, board of nursing rules and any state controlled substance regulations before offering treatment. A doctoral nurse preparing an organization's protocol should map each requirement, who may prescribe, under what agreement, with what training and documentation, so that clinicians know exactly what applies in their state.
What Has Not Changed
The waiver was only one barrier. Stigma among clinicians and pharmacies, pharmacy stocking practices, prior authorization requirements imposed by some insurers, and the limited availability of counseling and support services continue to limit treatment. Many clinicians who could prescribe did not, even when waivered, because of concerns about workload, diversion or lack of support. Removing a legal barrier makes treatment possible; making it common requires changes in practice and health systems.
Measuring whether prescribing actually increases will show whether the law achieved its purpose.
Implications for Advanced Practice Nurses
For advanced practice registered nurses, the change removes a federal obstacle and places responsibility on them and their organizations. Nurse practitioners in primary care, emergency, psychiatric and rural settings can now start buprenorphine without a separate waiver, subject to state law. Doing so well requires competence in assessment, induction, including newer approaches for patients using fentanyl, and follow-up, as well as collaboration with behavioral health services. Doctoral nurses can lead by building protocols and training within their organizations, working with pharmacies to ensure supply, and advocating for state laws that remove remaining practice restrictions, drawing on evidence that broader scope is associated with more prescribers where they are most needed.
Conclusion
Over two decades, federal law moved from excluding nurse practitioners from buprenorphine prescribing, to admitting them with heavier training requirements, to extending the authority to other advanced practice nurses, and finally to removing the special waiver altogether. Evidence from the waiver era shows that advanced practice nurses expanded access, especially in rural areas and where state law allowed full practice. Because state law still shapes practice, the full benefit of the federal change depends on state policy and on advanced practice nurses using their authority.
References
Barnett, M. L., Lee, D., & Frank, R. G. (2019). In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants. Health Affairs, 38(12), 2048-2056. https://doi.org/10.1377/hlthaff.2019.00859
Spetz, J., Toretsky, C., Chapman, S., Phoenix, B., & Tierney, M. (2019). Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. JAMA, 321(14), 1407-1408. https://doi.org/10.1001/jama.2019.0834
Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open, 3(2), Article e1920622. https://doi.org/10.1001/jamanetworkopen.2019.20622
Reading the DNP 820 Module 3 assignment instructions
Aspen keeps DNP 820 prompts in the classroom rather than on its public site, so this example follows the course description, which covers the legal and regulatory context of policy and the influence of legislation on care delivery. A law analysis paper usually asks you to select a statute or regulation, explain what it does, review evidence on its effects and discuss implications for nursing practice. Some prompts require a federal law; others accept state law. Check whether your instructor wants the bill's legislative history, the stakeholders involved or a position statement. Length and source rules vary, and legal sources such as the public law itself may need special APA formatting, so look at the style guidance your course provides before you build the reference list.
Inside the DNP 820 Module 3 example
At about 1,015 words, the example has six sections. The legislative sequence section lays out each law in date order and the specific change it made to prescribing rules. Evidence on the effects summarizes research on the growth in waivered clinicians, especially in rural areas. A section on state law explains that federal permission does not override state limits on nurse practitioner practice. What has not changed covers remaining barriers such as stigma, pharmacy stocking and payment. Implications for advanced practice nurses turn the analysis into action, including advocacy grounded in the evidence reviewed. The conclusion summarizes the legal arc and the continuing role of the states. Throughout, dates and statute names are given precisely so the reader can find each law.
Where the marks sit in the DNP 820 Module 3 rubric
The rubric for a law analysis will look first at whether you describe the law accurately, and then at the depth of your analysis of its effects. This example earns the accuracy points by listing each law with its year and its specific change, and the margin notes show why that factual base comes first. The analysis points come from pairing the federal change with evidence and with the limits imposed by state law, which shows an understanding of how policy actually works. Implications for practice are a common rubric row, and this paper addresses them with concrete steps. Organization is chronological, then analytic. APA credit depends on citing laws and journal articles correctly and on accurate dates throughout the paper.
Common DNP 820 Module 3 mistakes, and how to avoid them
A frequent mistake is describing a law from news coverage without reading what it actually changed. Use the law or a reliable legal summary. Students also treat federal changes as if they settle practice everywhere, forgetting that state scope-of-practice rules still apply to nurse practitioners. Another problem is presenting only the law and none of its effects; look for studies of what happened after it took effect. Papers sometimes mix up the X-waiver with the controlled substance registration all prescribers still need, which is an error graders spot quickly. Finally, keep the implications specific. General statements that nurses should advocate earn less than a named action, such as joining a state board committee or working with pharmacies on stocking.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Aspen University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More DNP 820 and DNP sample papers
- DNP 820 Module 1: A Policy Process Model Applied
- DNP 820 Module 2: Health Care Economics and Cost Drivers
- DNP 820 Module 4: Full Practice Authority Debate
- DNP 820 Module 5: The Regulatory Process and a Public Comment
- DNP 820 Module 6: Ethics of Allocating a Scarce Resource
- DNP 820 Module 7: Advocacy Brief to a State Legislator
- DNP 820 Module 8: Complete Policy Analysis With Recommendation
- DNP865 Module 3: Documentation Workflow Map
- DNP 852A Module 1: Planning the Final Chapter
- DNP 825 Module 1: Data Governance for a Nursing Project
- DNP845 Module 3: Grand vs Middle-Range Theory Paper
DNP 820 Module 3 questions, answered
What does DNP 820 Module 3 usually ask for?
Aspen's DNP 820 description includes the legal and regulatory context of policy, so analyzing a federal law that affects advanced practice nursing is a typical assignment. Check your classroom for the prompt.
Do nurse practitioners still need an X-waiver to prescribe buprenorphine?
No. Federal law removed the waiver requirement at the end of 2022. Practitioners need a DEA registration that includes Schedule III and must comply with state law and the federal training requirement.
Why does state scope of practice matter for a federal change?
Because states decide whether nurse practitioners may prescribe controlled substances independently. Evidence shows more waivered nurse practitioners in states with broader scope of practice.
Where can I find a free DNP 820 Module 3 sample paper?
You are looking at one. The page carries a complete analysis of the federal laws on buprenorphine prescribing and the advanced practice nurse's role, with its title page, sections, references and margin notes, free of charge. For an analysis of a different law, use the request form.
Do nurse practitioners still need an X-waiver after DNP 820 Module 3's law?
No. The Consolidated Appropriations Act, 2023 removed the X-waiver, so clinicians with a standard controlled substance registration can prescribe buprenorphine for opioid use disorder, subject to state law. This example explains that change and what still limits access.